(Date:5/16/2008)...sults demonstrating that TYKERB and trastuzumab to...on of progression-free survival (PFS), -- Combini...e and,outside of the HER2 receptor may create a mo...activity of TYKERB alone despite patients,previou... chemotherapy, LONDON and PHILADELPHIA, May 16 /P...
(Date:5/16/2008)...tically Significant Reductions in Selected ...to be published in 2008 Proceedings of the America...cology, SAN DIEGO, May 16 /PRNewswire-FirstCall/ ...nounced today that, in a registrational bioequival...tically significant reduction,in general disorders...
(Date:5/15/2008)...ta highlight safety profile of BSI-201 in ...ISBANE, Calif., May 15 /- BiPar Scien...any developing novel cancer therapies,today annou... BSI-201, will,be presented at the 2008 American S...ago., Findings will be presented from the first i...
(Date:5/15/2008)...RNewswire-FirstCall/ -- Schering-Plough,Corporatio... and treatment of,chronic hepatitis C virus (HCV) ...clinical studies with PEGINTRON(TM) (peginterferon...ion therapy, as well as boceprevir, the,company,s ...be presented at,the 39th annual Digestive Disease ...
Breaking Medicine Technology:GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 2ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 3ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 4ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 5BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 7Baltimore Washington Medical Center Hosts Day of Dance for Health 10732 1Baltimore Washington Medical Center Hosts Day of Dance for Health 10732 2Study finds widespread vitamin and mineral use among cancer survivors 10729 1Study finds widespread vitamin and mineral use among cancer survivors 10729 2Unilens Vision Inc Declares Regular Quarterly Cash Dividend of U S 240 09 Per Share 10722 1Unilens Vision Inc Declares Regular Quarterly Cash Dividend of U S 240 09 Per Share 10722 2Unintended Errors Leave Many Newborns Vulnerable 10721 1Unintended Errors Leave Many Newborns Vulnerable 10721 2... be published in an upcoming issue of,Anti-Cancer ...rapeutics Inc.,(TSX-V:PRX) today announced that tw... PRX 302. The Journal of the National Cancer,Insti...Dr. Sam,Denmeade and his team at Johns Hopkins Uni...he paper describes the Company,s compound,PRX302,...
...IFICANT CORRELATION BETWEEN,PLASMA LEVELS AND CLIN...t will host a conference call and live,webcast on ...f. (March 19, 2007) – Corcept Therapeutics,I...tudy 06, the,last of three Phase 3 trials evaluati...sychotic Major Depression (PMD), did not,achieve s...
Other Medicine Technology:Protox Announces Publication in Journal of the National Cancer,Institute Supporting PRX302 as Treatment for Prostatic Diseases 2Protox Announces Publication in Journal of the National Cancer,Institute Supporting PRX302 as Treatment for Prostatic Diseases 3Corcept Therapeutics Announces Phase 3 Study Evaluating Corlux for,Psychotic Major Depression Misses Primary Endpoint 2Corcept Therapeutics Announces Phase 3 Study Evaluating Corlux for,Psychotic Major Depression Misses Primary Endpoint 3Corcept Therapeutics Announces Phase 3 Study Evaluating Corlux for,Psychotic Major Depression Misses Primary Endpoint 4Corcept Therapeutics Announces Phase 3 Study Evaluating Corlux for,Psychotic Major Depression Misses Primary Endpoint 5(Date:5/16/2008)...Newswire/ -- Less than a week after,committing med...stated by,Cyclone Nargis, Project HOPE, an interna...e organization, is again mobilizing its full,resou...or the people of,central China devastated by the m...ives., "I am saddened by the vast loss of life an...
(Date:5/16/2008)...people who didn,t have cancer as children, study f... -- Adults who had cancer as children or teens are... a new study found. , And the heart problems s...d not suffer cancer as children. , Childhood ca...mes increased risk of having heart disease compare...
(Date:5/16/2008)...t The University of Texas M. D. Anderson Cancer Ce... leukemia cells by shutting down their energy sour...ical study, Lauren Akers, D.O., postdoctoral fello...erson, found that combining a novel glycolysis inh...duced more than 90 percent cell death in human tis...
(Date:5/16/2008)...hs School of Nursing and Midwifery, has won the In...an Nursing Awards. , Professor Rickard won top ... during testing procedures, reducing the risk of a...lready ill patients. The award was announced last ...inment complex. , Nurses routinely take blood s...
Breaking Medicine News(10 mins):Health News:Project HOPE to Send Humanitarian Assistance to China as Humanitarian Assistance to Myanmar Continues 2Health News:Childhood Cancer Survivors Prone to Early Heart Trouble 2Health News:Childhood Cancer Survivors Prone to Early Heart Trouble 3Health News:New drug combination brings 1-2 punch against acute leukemia 2Health News:Research talent wins national Innovation in Nursing award 2The Shandon Manual Staining Station is ideal for special processes, frozen sections, special stains and low volume procedures.
The Shandon Finesse 315 low-cost precision microtome is ergonomically designed to consistently produce high quality routine paraffin sections without user strain or fatigue.
The new Shandon HistocentreTM 3 is an integral part of the workflow in Histology laboratories, representing a workstation that complements any automatic tissue processor.
Shandon HistoWave is the answer to rapid tissue processing. It reduces time for fixation, tissue processing, decalification, immunochemistry and special stains.
Medicine Products: